Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy

Molecular Cancer
Yanyu PangGuan Jiang

Abstract

Tumor treatment is still complicated in the field of medicine. Tumor immunotherapy has been the most interesting research field in cancer therapy. Application of chimeric antigen receptor T (CAR-T) cell therapy has recently achieved excellent clinical outcome in patients, especially those with CD19-positive hematologic malignancies. This phenomenon has induced intense interest to develop CAR-T cell therapy for cancer, especially for solid tumors. However, the performance of CAR-T cell treatment in solid tumor is not as satisfactory as that in hematologic disease. Clinical studies on some neoplasms, such as glioblastoma, ovarian cancer, and cholangiocarcinoma, have achieved desirable outcome. This review describes the history and evolution of CAR-T, generalizes the structure and preparation of CAR-T, and summarizes the latest advances on CAR-T cell therapy in different tumor types. The last section presents the current challenges and prospects of CAR-T application to provide guidance for subsequent research.

References

Oct 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·F Letourneur, R D Klausner
Dec 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·G GrossZ Eshhar
Aug 1, 1995·Leukemia & Lymphoma·R H Scheuermann, E Racila
Oct 26, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael H KershawPatrick Hwu
Feb 15, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Julie R ParkMichael C Jensen
May 25, 2007·Seminars in Immunology·Catherine Mazza, Bernard Malissen
Feb 13, 2009·Proceedings of the National Academy of Sciences of the United States of America·Carmine CarpenitoCarl H June
Mar 6, 2009·PloS One·Dong-Joo CheonRichard R Behringer
Apr 23, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Michael C MiloneCarl H June
Sep 24, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Xiao-Song ZhongMichel Sadelain
May 5, 2011·The Journal of Clinical Investigation·Barbara SavoldoGianpietro Dotti
Aug 13, 2011·The New England Journal of Medicine·David L PorterCarl H June
Feb 20, 2013·Journal of Cell Science·Frances R BalkwillThorsten Hagemann
Mar 27, 2013·The New England Journal of Medicine·Stephan A GruppCarl H June
Feb 21, 2014·Science Translational Medicine·Marco L DavilaRenier Brentjens
Mar 4, 2014·Lancet·Nataliya Razumilava, Gregory J Gores
Mar 20, 2014·Nature Reviews. Clinical Oncology·Mark LinchCharlotte Benson
Oct 16, 2014·The New England Journal of Medicine·Shannon L MaudeStephan A Grupp
Dec 17, 2014·Immunological Reviews·Saar Gill, Carl H June
Mar 11, 2015·British Journal of Haematology·Sara GhorashianPersis Amrolia
Mar 25, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nabil AhmedStephen Gottschalk
Jul 2, 2015·Nature Reviews. Drug Discovery·Sjoukje J C van der StegenMichel Sadelain
Sep 1, 2015·Seminars in Oncology·Steven A FeldmanSteven A Rosenberg

❮ Previous
Next ❯

Citations

Feb 15, 2019·Expert Opinion on Biological Therapy·Martyna FilipskaRafael Rosell
Mar 26, 2019·Expert Review of Clinical Pharmacology·Davide BusatoMichele Dal Bo
Sep 17, 2018·Journal of Hematology & Oncology·Hanxiao XuKongming Wu
Oct 19, 2019·EMBO Molecular Medicine·Helmut R Salih, Gundram Jung
Jan 15, 2019·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Christian MarthAlain G Zeimet
Jul 29, 2020·Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research·Quan GuoSteve Jia
Apr 3, 2019·Journal of Hematology & Oncology·Anping LiKongming Wu
Nov 7, 2019·Molecular Cancer·Quande LinDelong Liu
Aug 8, 2020·Expert Review of Anticancer Therapy·Ioannis Ntanasis-StathopoulosTimothy M Pawlik
Jun 24, 2020·Journal of Hematology & Oncology·Minlin JiangCaicun Zhou
Oct 3, 2018·Cellular & Molecular Immunology·Paola Kučan BrlićStipan Jonjić
Jan 23, 2021·Cancer Biotherapy & Radiopharmaceuticals·Peng LüKeping Chen
Dec 1, 2020·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Huashan DuManhua Cui
Feb 22, 2021·Japanese Journal of Clinical Oncology·Eiji NakataToshifumi Ozaki
Aug 8, 2019·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Liang WangManhua Cui
Apr 4, 2021·International Journal of Molecular Sciences·Katarzyna M TerlikowskaSławomir J Terlikowski
Apr 1, 2021·Translational Oncology·Ehsan MoghanlooHabibollah Mahmoodzadeh
Dec 10, 2021·Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals·Othman Mohammad SalehWalaa Bayoumie El Gazzar

❮ Previous
Next ❯

Methods Mentioned

BETA
leukapheresis
xenograft
surgical resection

Clinical Trials Mentioned

NCT01044069
NCT01626495
NCT01029366
NCT01593696
NCT00466531
NCT01087294
NCT00881920
NCT02135406
NCT02030834
NCT01869166

Related Concepts

Related Feeds

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.